The Medicines Company (NASDAQ:MDCO) Files An 8-K Other EventsItem 8.01. Other Events
On November 15, 2016, The Medicines Company (the “Company”) issued a press release providing an update on the ORION-1 phase 2 study of inclisiran, its PCSK9 synthesis inhibitor. The Company is also presenting data from the ORION-1 phase 2 study at a Late-Breaking Clinical Trials session at the American Heart Association’s Scientific Sessions 2016. A copy of the press release issued by the Company on November 15, 2016, and a copy of the Company’s presentation made on November 15, 2016, are attached hereto as Exhibits 99.1 and 99.2, respectively.
Item 9.01. Exhibits
(d) Exhibits
99.1 Press release dated November 15, 2016
99.2 Presentation dated November 15, 2016
